F8 and hemophilia A: An open-label, nonrandomized study is also ongoing with the aim of evaluating the efficacy of SPK-8016 in adult males with severe hemophilia A without FVIII inhibitors and in the absence of neutralizing anti-AAV antibodies (NCT03734588) [41].